AKBA Akebia Therapeutics Inc.
19,966
$1.15
$0.01
(0.88%)
| Watchers | 19,966 |
| 52-Wk Low | $0.7801 |
| 52-Wk High | $2.48 |
| Market Cap | $241.04M |
| Volume | 532.00 |
| 52-Wk High | $2.48 |
| 52-Wk Low | $0.7801 |
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor ConferencePR Newswire • 6 days ago
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference PR Newswire CAMBRIDGE, Mass...
Share to Feed
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights PR...
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., May...
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (AKBA Research Report) and Precision BioSciences...
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) had its target price boosted by HC Wainwright from $5.00 to $6.00 in a research note issued on Thursday, Benzinga reports. The firm currently has...
Akebia Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis Akebia Receives FDA Approval of Vafseo (vadadustat...
Akebia Therapeutics (AKBA) has provided an update. Akebia Therapeutics, Inc. has made a significant stride in the healthcare market with the FDA's...